Sherlock Biosciences
Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts developing diagnostic tests using CRISPR-Cas13. The company was founded in 2019[1] by Feng Zhang, Omar Abudayyeh, and Jonathan Gootenberg of the Broad Institute. Cas13 was discovered by Zheng and Eugene Koonin using computational biology methods, and then further characterized by Jennifer Doudna's team at the University of California, Berkeley.[2] In 2020, both Sherlock Biosciences and Mammoth Biosciences from Doudna's lab at UC Berkeley used their similar CRISPR technologies to develop tests for COVID-19.[3]
See also[]
References[]
- ^ "Sherlock Biosciences". Craft.co. Retrieved 2021-05-27.
{{cite web}}: CS1 maint: url-status (link) - ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 423–425. ISBN 978-1-9821-1585-2.
- ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 427–433. ISBN 978-1-9821-1585-2.
 | This corporation or company article is a stub. You can help Wikipedia by . |
Categories:
- American companies established in 2019
- Biotechnology companies of the United States
- Health care companies based in Massachusetts
- Life sciences industry
- Medical diagnosis
- Company stubs